Expression of apoptotic protease-activating factor-1 in adenoid cystic carcinoma of the salivary glands and its clinicopathological relevance

Branko Dožić; Boban Aničić; Vladimir Sinobad; Nikola Miković; Srdjan Milanović; Ivan Dožić

doi:10.2298/VSP201026130D

Branko Dožić University of Belgrade, Faculty of Dental Medicine, Department of Pathology, Belgrade, Serbia
Boban Aničić University of Belgrade, Faculty of Dental Medicine, Clinic of Maxillofacial Surgery , Belgrade, Serbia
Vladimir Sinobad University of Belgrade, Faculty of Dental Medicine, Clinic of Maxillofacial Surgery, Belgrade, Serbia
Nikola Miković University of Belgrade, Faculty of Dental Medicine, Clinic of Maxillofacial Surgery, Belgrade, Serbia
Srdjan Milanović Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
Ivan Dožić University of Belgrade, Faculty of Dental Medicine, Department of Biochemistry, Belgrade, Serbia

DOI: https://doi.org/10.2298/VSP201026130D

Keywords: sex, apoptosis regulatory proteins, age factor, immunohistochemistry, apoptotic protease-activating factor, carcinoma, adenoid, cystic, survival

Abstract

Background/Aim. Apoptotic protease-activating factor-1 (Apaf-1) is a key molecule in the intrinsic or mitochondrial pathway of apoptosis. Some pathological conditions, such as cancer, stroke, and neurodegenerative diseases, are the result of dysregulation in the intrinsic apoptosis pathway. The aim of this study was to analyze the immunohistochemical expression of Apaf-1 in adenoid cystic carcinoma (ACC) cells of the salivary glands and its correlation with clinicopathological parameters of patients (gender, age, localization, histological type, and overall survival). Methods. Formalin-fixed, paraffin-embedded tissues of ACC of the salivary glands from 50 male and female patients with an average age of 58 years, were used for the study. We used the technique of tissue microarray (TMA blocks). Sections from the TMA mold, 5 μm thick, were stained with the streptavidin-biotin immunohistochemical technique using primary antibodies specific for Apaf-1 (Leica Biosystems, Newcastle, UK). Stained tissue sections were analyzed by the light microscope (Olympus type BH-2). Based on the data collected, the database was created in SPSS software v. 22.0 (SPSS Inc., Chicago, ILL, USA), which was used for further statistical analysis. The statistical data analysis included methods of descriptive and analytical (inferential) statistics. Results. The results of the immunohistochemical analysis of Apaf-1 expression in the samples of patients with ACC of the salivary glands were compared with the clinicopathological parameters of these patients. The immunohistochemical expression of Apaf-1 showed no statistical significance with regard to the patients’ gender (p = 0.552), age (p = 0.106), histological tumor type (p = 0.654), and localization of ACC in the salivary glands (p = 0.486). There was no statistically significant correlation observed between the overall survival of ACC patients and Apaf-1 expression in tumor cells (p = 0.340, Log-Rank test). Conclusion. With regard to ACC, Apaf-1 expression is not in correlation with clinicopathological parameters (gender, age, localization, histological tumor type, outcome of the disease, and overall survival). Therefore, we believe Apaf-1 cannot be regarded as an independent prognostic factor for course and outcome of ACC of the salivary glands.

References

Rossi DE, Baloch Z, Pusztaszeri M, Faquin CW. The Milan Sys-tem for Reporting Salivary Gland Cytopathology (MSRSGC): an ASC-IAC–sponsored system for reporting salivary gland fi-ne-needle aspiration. J Am Soc Cytopathol 2018; 7(3): 111‒8.

Guzzo M, Locati LD, Prott FJ, Gatta G, McGurk M, Licitra L. Major and minor salivary gland tumors. Crit Rev Oncol He-matol 2010; 74(2): 134‒48.

Ishida E, Ogawa T, Rokugo M, Ishikawa T, Wakamori S, Ohkoshi A, et al. Management of adenoid cystic carcinoma of the head and neck: a single-institute study with over 25-year follow-up. Head Face Med 2020; 16(1): 14.

Xu L, Li L, Zhang J, Cai W, Zhao S, Liu S. Accumulated cyto-toxicity of CDK inhibitor dinaciclib with first-line chemo-therapy drugs in salivary adenoid cystic carcinoma cells. Odon-tology 2020; 108(2): 300‒11.

Shizhi H, Pingdong L, Qi Z, Lizhen H, Zhenkun Y, Zhigang H, et al. Clinicopathologic and prognostic factors in adenoid cystic carcinoma of head and neck minor salivary glands: A clinical analysis of 130 cases. Am J Otolaryngol 2017; 38(2): 157‒62.

Liu HX, Wu M, Sun YM, Han FY, Liu YF, Zhang GZ. Prog-nostic value of human papillomavirus infection and p53, p16, epidermal growth factor receptor and p34cdc2 expression in patients with salivary adenoid cystic carcinoma. Int J Clin Exp Pathol 2017; 10(7): 7882‒9.

Acharyaa S, Annehosurb V, Hallikeri K, Shivappaa KS. Adenoid cystic carcinoma of the sublingual salivary gland: Case report of a rare clinical entity. J Oral Maxillofac Surg Med Pathol 2016; (28): 88–94.

Thierauf J, Ramamurthy N, Jo YV, Robinson H, Frazier PR, Gonzalez J, et al. Clinically Integrated Molecular Diagnostics in Adenoid Cystic Carcinoma. Oncologist 2019; 24(10): 1356–67.

Wong SHM, Kong WY, Fang CM, Loh HS, Chuah LH, Abdullah S, et al. The TRAIL to cancer therapy: Hindrances and poten-tial solutions. Crit Rev Oncol Hematol 2019; 143: 81‒94.

Gilmore A, King L. Emerging approaches to target mitochon-drial apoptosis in cancer cells. F1000Res 2019; 8: F1000 Fac-ulty Rev‒1793.

Noori AR, Hosseini ES, Nikkhah M, Hosseinkhani S. Apopto-some formation upon overexpression of native and truncated Apaf-1 in cell-free and cell-based systems. Arch Biochem Bio-phys 2018; 642: 46‒51.

Dorstyn L, Akey WC, Kumar S. New insights into apoptosome structure and function. Cell Death Differ 2018; 25(7): 1194–208.

Bratton SB, Salvesen GS. Regulation of the Apaf-1-caspase-9 apoptosome. J Cell Sci 2010; 123(Pt 19): 3209‒14.

Acehan D, Jiang X, Morgan DG, Heuser EJ, Wang X, Akey WC. Three-dimensional structure of the apoptosome: implications for assembly procaspase-9 binding and activation. Mol Cell 2002; 9(2): 423–32.

Dai DL, Martinka M, Bush JA, Li G. Reduced Apaf-1 expres-sion in human cutaneous melanomas. Br J Cancer 2004; 91(6): 1089–95.

Leo C, Richter C, Horn LC, Schütz A, Pilch H, Höckel M. Ex-pression of Apaf-1 in cervical cancer correlates with lymph node metastasis but not with intratumoral hypoxia. Gynecol Oncol 2005; 97(2): 602‒6.

Zlobec I, Minoo P, Baker K, Haegert D, Khetani K, Tornillo L, et al. Loss of APAF-1 expression is associated with tumour pro-gression and adverse prognosis in colorectal cancer. Eur J Cancer 2007; 43(6): 1101‒7.

Paik SS, Jang KS, Song YS, Jang SH, Min KW, Han HX, et al.. Reduced expression of Apaf-1 in colorectal adenocarcinoma correlates with tumor progression and aggressive phenotype. Ann Surg Oncol 2007; 14(12): 3453‒9.

Sträter J, Herter I, Merkel G, Hinz U, Weitz J, Möller P. Expres-sion and prognostic significance of APAF-1, caspase-8 and caspase-9 in stage II/III colon carcinoma: caspase-8 and caspa-se-9 is associated with poor prognosis. Int J Cancer 2010; 127(4): 873‒80.

Yamamura M, Sato Y, Takahashi K, Sasaki M, Harada K. The cyclin‑dependent kinase pathway involving CDK1 is a poten-tial therapeutic target for cholangiocarcinoma. Oncol Rep 2020; 43(1): 306‒17.

Geng X, Sun YY, Fu JJ, Cao L, Li Y. Role of miR-155-5p ex-pression and its involvement in apoptosis-related factors in thyroid follicular carcinoma. J Clin Pharm Ther 2020; 45(4): 660‒5.